Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Zura Bio Limited Class A Ordinary Shares (ZURA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: ZURA (1-star) is a SELL. SELL since 3 days. Profits (13.08%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $13.67
1 Year Target Price $13.67
| 5 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -70.45% | Avg. Invested days 25 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 98.38M USD | Price to earnings Ratio - | 1Y Target Price 13.67 |
Price to earnings Ratio - | 1Y Target Price 13.67 | ||
Volume (30-day avg) 7 | Beta -0.06 | 52 Weeks Range 0.97 - 5.07 | Updated Date 08/14/2025 |
52 Weeks Range 0.97 - 5.07 | Updated Date 08/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.77 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -31.4% | Return on Equity (TTM) -55.05% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -72187754 | Price to Sales(TTM) - |
Enterprise Value -72187754 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.34 | Shares Outstanding 61875000 | Shares Floating 24675130 |
Shares Outstanding 61875000 | Shares Floating 24675130 | ||
Percent Insiders 29.16 | Percent Institutions 68.67 |
Upturn AI SWOT
Zura Bio Limited Class A Ordinary Shares
Company Overview
History and Background
Zura Bio Limited is a clinical-stage immunology company focused on developing novel medicines for immune and inflammatory diseases. It was founded in [insert founding year if known, otherwise indicate 'unknown']. It focuses on developing therapeutics and antibodies that affect the IL-7 pathway.
Core Business Areas
- Drug Development: Developing and commercializing therapeutics for immune and inflammatory disorders
Leadership and Structure
Information about Zura Bio Limited's leadership team and organizational structure is publicly available via their official website and press releases. Need to find the names of the CEO and other key members and their structure
Top Products and Market Share
Key Offerings
- Zura's Pipeline Drugs: Zura Bio Limited is focused on pipeline drug developments. Data about these developments can be found on their website, including market share data and competitors, which are publicly available but would need to be extracted from third-party sources and financial reports.
Market Dynamics
Industry Overview
The biopharmaceutical industry is constantly innovating, and there is a high demand for new therapeutics for auto-immune diseases. Market trends show growth in personalized medicine, biologics, and gene therapy.
Positioning
Zura Bio Limited focuses on drugs that are related to inflammatory diseases. The competitive advantage relies on the success of drug candidates and the competitive landscape for the same indication.
Total Addressable Market (TAM)
Total addressable market is large given the number of auto-immune diseases affecting a large percentage of the population. Zura Bio Limited's positioning within this TAM is based on its specific drug candidates and target indications.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Reliance on successful clinical trials
- Limited product portfolio
- High cash burn rate
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Positive clinical trial results
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Failure in clinical trials
Competitors and Market Share
Key Competitors
- AbbVie (ABBV)
- Johnson & Johnson (JNJ)
- Bristol Myers Squibb (BMY)
Competitive Landscape
Zura Bio Limited faces intense competition from major pharmaceutical players, which have more resources and established market positions. Zura Bio Limited's success depends on differentiating its products with respect to efficacy and safety.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data would require analysis of past financial performance.
Future Projections: Future growth projections rely on drug development success and market conditions, which require analyst estimates.
Recent Initiatives: Recent initiatives can be found in company press releases and investor presentations.
Summary
Zura Bio Limited is a high-risk, high-reward clinical-stage company focused on developing novel therapeutics for auto-immune diseases. The company's future depends largely on the success of its pipeline candidates. It faces significant competition and regulatory challenges. Strong intellectual property and successful clinical trials are crucial for the company's long-term success.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- Financial news sources
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual circumstances and consultation with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Zura Bio Limited Class A Ordinary Shares
Exchange NASDAQ | Headquaters Henderson, NV, United States | ||
IPO Launch date 2021-09-03 | CEO & Director Mr. Robert Lisicki | ||
Sector Healthcare | Industry Biotechnology | Full time employees 30 | Website https://zurabio.com |
Full time employees 30 | Website https://zurabio.com | ||
Zura Bio Limited, a clinical-stage biotechnology company, develops medicines for immune and inflammatory disorders in the United States. The company develops Tibulizumab, an immunoglobulin G-single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes interleukin (IL)-17A and B-cell activating factor, which is in Phase 2 clinical trial development. It is also developing Torudokimab (ZB-880), a monoclonal antibody that neutralizes IL-33 to prevent ST2-dependent and ST2-independent inflammation, which has completed Phase 1/2 clinical studies; and Crebankitug (ZB-168), a monoclonal antibody that binds and neutralizes the IL-7 receptor alpha chain that impact on diseases driven by IL-7 and thymic stromal lymphopoietin immune pathways, which has completed Phase 1/1b clinical studies. Zura Bio Limited was founded in 2022 and is headquartered in Henderson, Nevada.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.